Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis

J Card Surg. 2017 Jul;32(7):443-446. doi: 10.1111/jocs.13165. Epub 2017 Jun 19.

Abstract

Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long-term survival without further intervention.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Heart Diseases / drug therapy*
  • Heart Diseases / etiology*
  • Heart-Assist Devices / adverse effects*
  • Humans
  • Infusions, Intravenous
  • Male
  • Thrombosis / drug therapy*
  • Thrombosis / etiology*
  • Tissue Plasminogen Activator / administration & dosage*
  • Treatment Outcome

Substances

  • Tissue Plasminogen Activator